

1 CLAIMS

- 2
- 3 1. A marker for bladder cancer, prostate cancer or
4 urinary infection, the marker consisting a 37KDa
5 fragment of EGFR.
- 6
- 7 2. A method for the diagnosis of first presentation
8 or recurrence of bladder cancer, the method
9 consisting of the detection of a 37KDa fragment of
10 EGFR in a urine sample.
- 11
- 12 3. A method as claimed in claim 2 wherein the
13 presence of the 37KDa EGFR fragment is detected
14 using an antibody.
- 15
- 16 4. A method as claimed in claim 2 or claim 3 wherein
17 the presence of 37KDa EGFR fragment is detected
18 using antibody Ab4 EGFR available from Oncogene
19 Science, Inc.
- 20
- 21 5. The use of antibody Ab4 EGFR in a test to detect
22 the presence of 37KDa EGFR fragment in urine as a
23 diagnostic test for bladder cancer.
- 24
- 25 6. A method for the diagnosis of prostate cancer, the
26 method comprising the detection of a 37KDa
27 fragment of EGFR in a urine sample.
- 28
- 29 7. A method as claimed in claim 6 wherein the
30 presence of the 37KDa EGFR fragment is detected
31 using an antibody.
- 32
- 33 8. A method as claimed in claim 6 or claim 7 wherein
34 the presence of 37KDa EGFR fragment is detected
35 using antibody Ab4 EGFR available from Oncogene
36 Science, Inc.

FOOED "S2590360

16

- 1 9. The use of antibody ~~Ab4~~ EGFR in a test to detect
2 the presence of 37KDa EGFR fragment in urine as a
3 diagnostic test for prostate cancer.
4
- 5 10. A method for the diagnosis of bladder cancer,
6 and/or prostate cancer and/or urinary infection,
7 the method comprising a test for the presence of a
8 37KDa fragment of EGFR in a urine sample.
9
- 10 11. A method as claimed in any of claims 2 to 4 and 7
11 to 10 in the form of a dip-stick test.
12
- 13 12. The use of antibodies to the 37KDa fragment of
14 EGFR in the diagnosis of urinary infection,
15 bladder cancer and prostate cancer.
16